Clinical Relevance of Biomarkers of Oxidative Stress

被引:635
作者
Frijhoff, Jeroen [1 ]
Winyard, Paul G. [2 ]
Zarkovic, Neven [3 ]
Davies, Sean S. [4 ,5 ]
Stocker, Roland [6 ,7 ]
Cheng, David [6 ]
Knight, Annie R. [2 ]
Taylor, Emma Louise [2 ]
Oettrich, Jeannette [1 ]
Ruskovska, Tatjana [8 ]
Gasparovic, Ana Cipak [3 ]
Cuadrado, Antonio [9 ,10 ,11 ,12 ]
Weber, Daniela [13 ]
Poulsen, Henrik Enghusen [14 ,15 ]
Grune, Tilman [13 ]
Schmidt, Harald H. H. W. [1 ]
Ghezzi, Pietro [16 ]
机构
[1] Maastricht Univ, Cardiovasc Res Inst Maastricht CARIM, Fac Hlth Med & Life Sci, Maastricht, Netherlands
[2] Univ Exeter, Sch Med, Exeter, Devon, England
[3] Rudjer Boskovic Inst, LabOS, Zagreb, Croatia
[4] Vanderbilt Univ, Dept Med, Nashville, TN USA
[5] Vanderbilt Univ, Dept Pharmacol, Div Clin Pharmacol, Nashville, TN USA
[6] Victor Chang Cardiac Res Inst, Vasc Biol Div, Darlinghurst, NSW, Australia
[7] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia
[8] Goce Delcev Univ, Fac Med Sci, Stip, Macedonia
[9] ISCIII, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain
[10] UAM CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain
[11] Inst Invest Sanitaria La Paz IdiPaz, Madrid, Spain
[12] Autonomous Univ Madrid, Fac Med, Dept Biochem, E-28049 Madrid, Spain
[13] German Inst Human Nutr Potsdam Rehbrucke, Dept Mol Toxicol, Nuthetal, Germany
[14] Univ Copenhagen, Fac Hlth Sci, Copenhagen, Denmark
[15] Bispebjerg Frederiksberg Hosp, Copenhagen, Denmark
[16] Brighton & Sussex Med Sch, Brighton, E Sussex, England
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
LOW-DENSITY-LIPOPROTEIN; ADVANCED GLYCATION ENDPRODUCTS; PROTEIN-TYROSINE NITRATION; POLYCYSTIC-OVARY-SYNDROME; TANDEM MASS-SPECTROMETRY; ACUTE-RENAL-FAILURE; LIPID-PEROXIDATION; ENDOTHELIAL DYSFUNCTION; ISOPROSTANE PATHWAY; REDOX STATE;
D O I
10.1089/ars.2015.6317
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Significance: Oxidative stress is considered to be an important component of various diseases. A vast number of methods have been developed and used in virtually all diseases to measure the extent and nature of oxidative stress, ranging from oxidation of DNA to proteins, lipids, and free amino acids. Recent Advances: An increased understanding of the biology behind diseases and redox biology has led to more specific and sensitive tools to measure oxidative stress markers, which are very diverse and sometimes very low in abundance. Critical Issues: The literature is very heterogeneous. It is often difficult to draw general conclusions on the significance of oxidative stress biomarkers, as only in a limited proportion of diseases have a range of different biomarkers been used, and different biomarkers have been used to study different diseases. In addition, biomarkers are often measured using nonspecific methods, while specific methodologies are often too sophisticated or laborious for routine clinical use. Future Directions: Several markers of oxidative stress still represent a viable biomarker opportunity for clinical use. However, positive findings with currently used biomarkers still need to be validated in larger sample sizes and compared with current clinical standards to establish them as clinical diagnostics. It is important to realize that oxidative stress is a nuanced phenomenon that is difficult to characterize, and one biomarker is not necessarily better than others. The vast diversity in oxidative stress between diseases and conditions has to be taken into account when selecting the most appropriate biomarker. Antioxid. Redox Signal. 23, 1144-1170.
引用
收藏
页码:1144 / 1170
页数:27
相关论文
共 200 条
[1]   Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study [J].
Abbasi, Ali ;
Corpeleijn, Eva ;
Gansevoort, Ron T. ;
Gans, Rijk O. B. ;
Struck, Joachim ;
Schulte, Janin ;
Hillege, Hans L. ;
van der Harst, Pim ;
Stolk, Ronald P. ;
Navis, Gerjan ;
Bakker, Stephan J. L. .
DIABETOLOGIA, 2014, 57 (09) :1842-1849
[2]   Guidance on the scientific requirements for health claims related to antioxidants, oxidative damage and cardiovascular health [J].
Agostoni, Carlo ;
Bresson, Jean-Louis ;
Fairweather-Tait, Susan ;
Flynn, Albert ;
Golly, Ines ;
Korhonen, Hannu ;
Lagiou, Pagona ;
Lovik, Martinus ;
Marchelli, Rosangela ;
Martin, Ambroise ;
Moseley, Bevan ;
Neuhauser-Berthold, Monika ;
Przyrembel, Hildegard ;
Salminen, Seppo ;
Sanz, Yolanda ;
Strain, Sean ;
Strobel, Stephan ;
Tetens, Inge ;
Tome, Daniel ;
van Loveren, Hendrik ;
Verhagen, Hans .
EFSA JOURNAL, 2011, 9 (12)
[3]   Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidiseds GC [J].
Ahrens, Ingo ;
Habersberger, Jonathon ;
Baumlin, Nadege ;
Qian, Hongwei ;
Smith, Belinda K. ;
Stasch, Johannes-Peter ;
Bode, Christoph ;
Schmidt, Harald H. H. W. ;
Peter, Karlheinz .
ATHEROSCLEROSIS, 2011, 218 (02) :431-434
[4]   Peroxynitrite reactivity with amino acids and proteins [J].
Alvarez, B ;
Radi, R .
AMINO ACIDS, 2003, 25 (3-4) :295-311
[5]   URIC-ACID PROVIDES AN ANTIOXIDANT DEFENSE IN HUMANS AGAINST OXIDANT-CAUSED AND RADICAL-CAUSED AGING AND CANCER - A HYPOTHESIS [J].
AMES, BN ;
CATHCART, R ;
SCHWIERS, E ;
HOCHSTEIN, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1981, 78 (11) :6858-6862
[6]   Lipoperoxidation and protein oxidative damage exhibit different kinetics during septic shock [J].
Andresen, Max ;
Regueira, Tomas ;
Bruhn, Alejandro ;
Perez, Druso ;
Strobel, Pablo ;
Dougnac, Alberto ;
Marshall, Guillermo ;
Leighton, Federico .
MEDIATORS OF INFLAMMATION, 2008, 2008
[7]   N-Acetylcysteine -: a safe antidote for cysteine/glutathione deficiency [J].
Atkuri, Kondala R. ;
Mantovani, John J. ;
Herzenberg, Leonard A. ;
Herzenberg, Leonore A. .
CURRENT OPINION IN PHARMACOLOGY, 2007, 7 (04) :355-359
[8]  
AWAD JA, 1993, J BIOL CHEM, V268, P4161
[9]   Anti-inflammatory therapies for atherosclerosis [J].
Back, Magnus ;
Hansson, Goran K. .
NATURE REVIEWS CARDIOLOGY, 2015, 12 (04) :199-211
[10]   The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma [J].
Baker, AF ;
Dragovich, T ;
Tate, WR ;
Ramanathan, RK ;
Roe, D ;
Hsu, CH ;
Kirkpatrick, DL ;
Powis, G .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 2006, 147 (02) :83-90